Accumulation of Foxp3+ Tregs in syngeneic mouse gliomas has also been described and depletion of Tregs with CD25-specific immunoglobulins can induce tumor regression and improve survival in these preclinical models [25], [32], [33]. This evidence concerns the gene FOXP3 and central nervous system cancer.